Redeye provides a research update following the Q4 report recently published by Newbury.
Sales -8% vs. ABGSCe (-11% y-o-y), adj. EBIT -7% vs.
Redeye provides a note about CLS’s decision to concentrate fully on its neurosurgery business.
Pharma Equity Group (“PEG” or “the Company”) announced on Wednesday, October the 23rd, that the Comp...
Organic growth of 31%, +6pp vs. ABGSCe Significant EBITDA improvement Likely positive consensus esti...
Sales +1% and adj. EBIT +2% vs. ABGSCe Operating cash flow SEK 42m, vs ABGSCe SEK -47m Minor positiv...
Atria reported Q3 adjusted EBIT of EUR 25.8m, 35% (EUR 6.
Redeye updates its estimates and valuation following Lifco releasing its Q3 2024 report.
Redeye anticipates the Lifecare division to maintain its solid performance in Q3 2024, though weaker...
Redeye comments on the Q3 report released earlier this morning.
During October, Cibus has acquired three grocery stores in Finland for EUR 14.
Ahead of CapMan's Q3 report due on 7 November, we revise our estimates to reflect the divestment of ...
Administer announced yesterday that it will lower its revenue guidance to EUR 74-76m, while narrowin...
Miss on Q3 sales (-12%) and EBITDA (-10%) vs ABGSCe China faced headwinds due to macroeconomic facto...
Top-line estimate cuts partly mitigated by lower rates Outgrowing the sector on high share of floati...
Redeye provides its initial take on Lifco’s Q3 2024 report, which broadly aligned with our estimates...
Q3 report Friday, 25 October, 07:00 CET '24e-'26e EBITA up 0-2%; 7% CAGR '23-'26e 13-10x EBITA '24e-...
We expect Svedbergs Group's Q3 report on 25 October to show a decent quarter, with 1% organic sales ...
Q3e: 13% sales growth, 15% EBITA growth 12-7x EBITA in M&A scenario; potential for 30% EBITA CAGR We...
Q3e: stable sales (-1% org. growth), -6% adj. EBITA y-o-y Minor estimate changes: 2% lower sales in ...
